Pharsight

1. List of Fyarro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786	AADI	Nanoparticle comprising rapamycin and albumin as anticancer agent	Feb, 2029 (5 years from now)
US10206887	AADI	Prion free nanoparticle compositions and methods of making thereof	Apr, 2030 (7 years from now)
US10705070	AADI	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug	Mar, 2036 (12 years from now)
US10973806	AADI	Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin	Jun, 2036 (13 years from now)
US11497737	AADI	NA	Oct, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Nov 22, 2024
Orphan Drug Exclusivity (ODE)	Nov 22, 2028

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle

Dosage: POWDER;INTRAVENOUS